Trial
NCT04901299
Fulvestrant + Neratinib In Breast Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Massachusetts General Hospital
Collaborators
Celcuity Inc; Puma Biotechnology, Inc.
Condition
Stage IV (Metastatic) Breast Cancer
Intervention
NERATINIB
Why stopped
Team decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-01